tbuckley/cabot-search huggingface dataset:
Are Temporal Artery Biopsy Findings Related to PET/CT Findings in Giant Cell Arteritis?
Authors: Jaume Mestre-Torres, Fernando Martínez-Valle, Alejandra Gabaldón, Marc Simó-Perdigó, M. Teresa Salcedo-Allende, Ignacio Navales-Mateu, Roser Solans-Laqué
Journal: Clinical Nuclear Medicine (2022)

Background Two clinical subsets of giant cell arteritis have been identified with different histological and CT findings. However, PET/CT findings have not been compared with temporal artery biopsy (TAB). Objective The aims of this study were to describe clinical and histological findings in patients with giant cell arteritis according to the presence or absence of aortitis in PET/CT at the disease diagnosis, and to identify independent factors related to aortic involvement. Methods Patients were included and followed prospectively. Clinical symptoms and TAB findings were recorded. PET/CT was performed in the first 10 days of steroid therapy. Aortitis was defined if a grade 3 uptake on visual analysis was present on arterial wall. Clinical and histological variables were compared according to the presence or absence of aortitis on PET/CT. Multivariate analysis was performed to identify independent factors related to the presence of aortitis. Results Twenty-seven patients (median age, 77.6 years) were included. PET/CT was performed with a median delay of 5.0 days. Aortitis was observed in 8 patients. Patients with aortitis were younger (69.9 vs 83.7 years, P = 0.04) and had less frequently ischemic manifestations (25.0% vs 84.2%, P = 0.006) than patients without aortitis. Giant multinucleated cells were more frequent on TAB from patients with aortitis (71.4% vs 16.7%), and its presence was an independent risk factor for the occurrence of aortic involvement on PET/CT (odds ratio, 12.2; P = 0.046). Conclusions Our study shows that giant cells on TAB are associated with the presence of aortitis on PET/CT. Patients with aortic involvement are younger and show less frequently ischemic manifestations.
SPLENECTOMY APPEARS TO EXERT PROTECTIVE EFFECT FROM PREVIOUSLY REPORTED ASSOCIATION BETWEEN IMMUNE THROMBOCYTOPENIC (ITP) PATIENTS WITH AORTIC VALVE DISEASE
Authors: Fathima Haseefa, Mohammad Reza Movahed, Mehrtash Hashemzadeh, Mehrnoosh Hashemzadeh
Journal: Journal of the American College of Cardiology (2022)
Small Cell Lung Cancer—A Neglected Disease With More Data Needed
Authors: Alberto Ruano-Raviña, Mariano Provencio-Pulla, Mónica Pérez-Ríos
Journal: JAMA Network Open (2022)

Jeng-Sen Tseng, MD, PhD; Chun-Ju Chiang, PhD; Kun-Chieh Chen, MD, PhD; Zhe-Rong Zheng, MD; Tsung-Ying Yang, MD, PhD; Wen-Chung Lee, MD, PhD; Kuo-Hsuan Hsu, MD; Yen-Hsiang Huang, MD; Tsang-Wu Liu, MD; Jiun-Yi Hsia, MD, PhD; Gee-Chen Chang, MD, PhD
Nitric Oxide Delivering Surfaces: An Overview of Functionalization Strategies and Efficiency Progress
Authors: Jordan Beurton, Ariane Boudier, Amedea Barozzi Seabra, Nihal Engin Vrana, Igor Clarot, Philippe Lavalle
Journal: Advanced Healthcare Materials (2022)

Abstract An overview on the design of nitric oxide (NO) delivering surfaces for biomedical purposes is provided, with a focus on the advances of the past 5 years. A localized supply of NO is of a particular interest due to the pleiotropic biological effects of this diatomic compound. Depending on the generated NO flux, the surface can mimic a physiological release profile to provide an activity on the vascular endothelium or an antibacterial activity. Three requirements are considered to describe the various strategies leading to a surface delivering NO. Firstly, the coating must be selected in accordance with the properties of the substrate (nature, shape, dimensions…). Secondly, the releasing and/or generating kinetics of NO should match the targeted biological application. Currently, the most promising structures are developed to provide an adaptable NO supply driven by pathophysiological needs. Finally, the biocompatibility and the stability of the surface must also be considered regarding the expected residence time of the device. A critical point of view is proposed to help readers in the design of the NO delivering surface according to its expected requirement and therapeutic purpose.
INCIDENT HYPERTENSION AND CLINICAL OUTCOMES AFTER ACALABRUTINIB INITIATION FOR B-CELL MALIGNANCIES
Authors: Sunnia T. Chen, Leylah Azali, Lindsay Rosen, Qiuhong Zhao, Tracy Wiczer, Marilly Palettas, John Gambril, Onaopepo Kola-Kehinde, Patrick Ruz, Kerry Rogers, Adam Kittai, Michael Grever, Farrukh Awan, John C. Byrd, Seema A. Bhat, Daniel Addison
Journal: Journal of the American College of Cardiology (2022)
SYSTEMIC SARCOIDOSIS WITH ACUTE MYOCARDIAL INVOLVEMENT RESEMBELING MALIGNANCY
Authors: Loba Alam, Kevin Rabii, Otobo Emamuzo, Swiri Konje, Yeraz Kachatoorian, Glenmore U. Lasam, Soheila Talebi
Journal: Journal of the American College of Cardiology (2022)
PHYSICIAN-INDUCED DEMAND FOR ACUTE CARDIOVASCULAR INPATIENT CARE IN JAPAN: AN ANALYSIS OF 3,546,181 ADMISSIONS FROM JROAD DATABASE
Authors: Yoshiaki Ohyama, Michikazu Nakai, Yoko Sumita, Yoshitaka Iwanaga, Tetsuya Nakamura, Masahiko Kurabayashi, Kazuaki Negishi
Journal: Journal of the American College of Cardiology (2022)
RISK PROFILE AND OUTCOMES OF PATIENTS WITH PREMATURE AND EXTREMELY PREMATURE CORONARY ARTERY DISEASE COMPARED WITH OLDER ADULTS: ANALYSIS OF THE CARDIAC REGISTRY OF PAKISTAN (CROP) DATABASE
Authors: Waqas Ullah, Rehan Malik, Mahboob Alam, Salim S. Virani, Bashir Hanif
Journal: Journal of the American College of Cardiology (2022)
Impact of COVID-19 and malaria coinfection on clinical outcomes: a retrospective cohort study
Authors: Rasha Hussein, Murilo Guedes, Nada Ibraheim, Mazin M. Ali, Amal El-Tahir, Nahla Allam, Hussain Abuakar, Roberto Pecoits-Filho, Peter Kotanko
Journal: Clinical Microbiology and Infection (2022)

Despite the possibility of concurrent infection with COVID-19 and malaria, little is known about the clinical course of coinfected patients. We analysed the clinical outcomes of patients with concurrent COVID-19 and malaria infection.We conducted a retrospective cohort study that assessed prospectively collected data of all patients who were admitted between May and December 2020 to the Universal COVID-19 treatment center (UCTC), Khartoum, Sudan. UCTC compiled demographic, clinical, laboratory (including testing for malaria), and outcome data in all patients with confirmed COVID-19 hospitalized at that clinic. The primary outcome was all-cause mortality during the hospital stay. We built proportional hazard Cox models with malaria status as the main exposure and stepwise adjustment for age, sex, cardiovascular comorbidities, diabetes, and hypertension.We included 591 patients with confirmed COVID-19 diagnosis who were also tested for malaria. Mean (SD) age was 58 (16.2) years, 446/591 (75.5%) were males. Malaria was diagnosed in 270/591 (45.7%) patients. Most malaria patients were infected by Plasmodium falciparum (140/270; 51.9%), while 121/270 (44.8%) were coinfected with Plasmodium falciparum and Plasmodium vivax. Median follow-up was 29 days. Crude mortality rates were 10.71 and 5.87 per 1000 person-days for patients with and without concurrent malaria, respectively. In the fully adjusted Cox model, patients with concurrent malaria and COVID-19 had a greater mortality risk (hazard ratio 1.43, 95% confidence interval 1.21-1.69).Coinfection with COVID-19 and malaria is associated with increased all-cause in-hospital mortality compared to monoinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Association of Screen Time With Internalizing and Externalizing Behavior Problems in Children 12 Years or Younger
Authors: Rachel Eirich, Brae Anne McArthur, Ciana Anhorn, Claire McGuinness, Dimitri A. Christakis, Sheri Madigan
Journal: JAMA Psychiatry (2022)

Currently, there is a lack of consensus in the literature on the association between screen time (eg, television, video games) and children's behavior problems.To assess the association between the duration of screen time and externalizing and internalizing behavior problems among children 12 years or younger.For this systematic review and meta-analysis, MEDLINE, Embase, and PsycINFO databases were searched for articles published from January 1960 to May 2021. Reference lists were manually searched for additional studies.Included studies measured screen time (ie, duration) and externalizing or internalizing behavior problems in children 12 years or younger, were observational or experimental (with baseline data), were available in English, and had data that could be transformed into an effect size. Studies conducted during the COVID-19 pandemic were excluded. Of 25 196 nonduplicate articles identified and screened for inclusion, 595 met the selection criteria.The study followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. Extracted variables were child age, sex, and socioeconomic status; informants and measurement type for screen time and behavior problems; study publication year; and study design and quality. Data were extracted by 2 independent coders and were pooled using a random-effects model.The primary outcome was the association of screen time duration with externalizing (eg, aggression, attention deficit/hyperactivity disorder symptoms) and internalizing (eg, depression, anxiety) behaviors or diagnoses.Of the 595 full-text articles assessed for eligibility, 87 studies met all inclusion criteria, comprising 98 independent samples and 159 425 participants (mean [SD] age, 6.07 [2.89] years; 83 246 [51.30%] male). Increased duration of screen time had a small but significant correlation with more externalizing problems (90 samples; r, 0.11; 95% CI, 0.10-0.12) and internalizing problems (43 samples; r, 0.07; 95% CI, 0.05-0.08) in children. Several methodological moderators explained between-study heterogeneity. There was evidence of significant between study heterogeneity (I2 = 87.80).This systematic review and meta-analysis found small but significant correlations between screen time and children's behavior problems. Methodological differences across studies likely contributed to the mixed findings in the literature.
Reporting of Participant Race and Ethnicity in Published US Pediatric Clinical Trials From 2011 to 2020
Authors: Chris A. Rees, Amanda M. Stewart, Sagar Mehta, Elorm Avakame, Jasmyne Jackson, Jheanelle McKay, Elyse N. Portillo, Kenneth A. Michelson, Christopher P. Duggan, Eric W. Fleegler
Journal: JAMA Pediatrics (2022)

<h3>Importance</h3> Equitable representation of participants who are members of racial and ethnic minority groups in clinical trials enhances inclusivity in the scientific process and generalizability of results. <h3>Objective</h3> To assess participant race and ethnicity in pediatric clinical trials published from 2011 to 2020. <h3>Design, Setting, and Participants</h3> This cross-sectional study examined articles reporting pediatric clinical trials conducted in the US published in 5 leading general pediatric and 5 leading general medical journals from January 1, 2011, to December 31, 2020. <h3>Main Outcomes and Measures</h3> Reporting of participant race and ethnicity and comparison of enrolled participants vs US census populations of pediatric racial and ethnic groups in published clinical trials. <h3>Results</h3> The study included 612 articles reporting pediatric clinical trials during the study period, with 565 618 total participants (median per trial, 200 participants [IQR, 90-571 participants]). Of the 612 articles, 486 (79.4%) reported participant race and 338 (55.2%) reported participant ethnicity. From 2011 to 2020, relative rates of reporting of participant race increased by 7.9% per year (95% CI, 0.2%-16.3% per year) and reporting of ethnicity increased by 11.4% per year (95% CI, 4.8%-18.4% per year). Among articles reporting race and ethnicity, the method of assignment was not reported in 261 of 511 articles (51.1%) and 207 of 359 articles (57.7%), respectively. Black/African American children were enrolled proportionally more than the US population of Black/African American children (odds ratio [OR], 1.88; 95% CI, 1.87-1.89). Hispanic/Latino children were enrolled commensurately with the US population of Hispanic/Latino children (OR, 1.02; 95% CI, 1.01-1.03). American Indian/Alaska Native (OR, 0.82; 95% CI, 0.79-0.85), Asian (OR, 0.56; 95% CI, 0.55-0.57), and Native Hawaiian/Pacific Islander (OR, 0.66; 95% CI, 0.61-0.72) children were enrolled significantly less compared with the respective US populations of these groups. White children were enrolled less than expected (OR, 0.84; 95% CI, 0.84-0.85) but represented 188 156 (46.0%) of participants in trials reporting race or ethnicity. <h3>Conclusions and Relevance</h3> This cross-sectional study revealed that the proportion of published pediatric clinical trials that reported participant race and ethnicity increased from 2011 to 2020, but participant race and ethnicity were still underreported. Disparities existed in pediatric clinical trial enrollment of American Indian/Alaska Native, Asian, and Native Hawaiian/Pacific Islander children. The greater representation of Black/African American children compared with the US population suggests inclusive research practices that could be extended to other historically disenfranchised racial and ethnic groups.
UNCOVERING INDIVIDUAL HETEROGENEITY IN PATIENTS WITH ST ELEVATION MYOCARDIAL INFARCTION USING AUTOMATED COMPUTATIONAL MODELLING OF DEMOGRAPHIC, CLINICAL, AND ECHOCARDIOGRAPHIC ATTRIBUTES OF RISK
Authors: Muhammad Saad, Timothy J. Vittorio, Sudharshan Reddsgongati, Upreti Prakash, Neelanjana Pandey, Christopher Taylor, Nicole Ditommaso, Sarthak Kulshrestha, Jonathan N. Bella, Nassim Rostane Krim, Ala Omar
Journal: Journal of the American College of Cardiology (2022)
DOES INPATIENT PREOPERATIVE CARDIAC WORKUP IMPROVE PATIENT OUTCOMES?
Authors: Adee Elhamdani, Laith Alhuneafat, Amel Tobaa, Mian Tanveer Ud Din, Arinze Bosah, Kirtivardhan Vashistha, Mark Doyle, Adnan Khalif, Indu G. Poornima
Journal: Journal of the American College of Cardiology (2022)
CHANGE IN TRICUSPID REGURGITATION SEVERITY OVER TIME AFTER TRANSVENOUS PACEMAKER AND DEFIBRILLATOR LEAD EXTRACTION
Authors: Marc Allard-Ratick, Nikita Wadhwani, Dingxin Qin, Jay Khambhati, Nathaniel B. Langer, Evin Yucel, Leon M. Ptaszek, Theofanie Mela, Sammy Elmariah
Journal: Journal of the American College of Cardiology (2022)
COMPARED THE CLINICAL OUTCOMES OF CLOPIDOGREL AND TICAGRELOR IN STABILIZED PATIENTS WITH ACUTE CORONARY SYNDROME AFTER PERCUTANEOUS CORONARY INTERVENTION: RESULTS FROM A REAL-WORLD REGISTRY
Authors: Yunnan Zhang, Jialun Han, Xiujin Shi, Wenxing Peng, Yang Lin
Journal: Journal of the American College of Cardiology (2022)
Digenic Inheritance of Dominant TRAF6 and Recessive OSMR Pathogenic Variants Associated with Short Stature, Atopy, and Eosinophilic Inflammation
Authors: Alyssa James, Yihui Liu, Lynne Wolfe, Jack Chovanec, Michael O’Connell, Kate Lee, Julie Niemela, Carlos Ferreira, Thomas DiMaggio, Angeliki Makri, Michael Boehnke, Tara Weixel, Leena Kinnunen, Andrew Oler, James Connelly, Daniel Dulek, Yasmin Khan, Angela Delaney, Youn Hee Jee, Sergio Rosenzweig, Joshua Milner, Heikki Koistinen, Ellen Macnamara, David Adams, William Gahl, Jonathan Lyons
Journal: Journal of Allergy and Clinical Immunology (2022)
Commentary
Authors: Partha Pal, D. Nageshwar Reddy
Journal: Endoscopy (2022)

Post-cholecystectomy complete transection of bile duct poses a significant management challenge that warrants surgical repair or percutaneous–endoscopic reconnection. Purely endoscopic reconnection, with staged internal biliary drainage using combined endoscopic retrograde cholangiopancreatography (ERCP) and endosonography followed by definitive endoscopic repair has been described.
FREQUENCY AND PREDICTORS OF ALL-CAUSE IN-HOSPITAL MORTALITY IN TRANSCATHETER MITRAL VALVE REPLACEMENT: A NATIONWIDE INPATIENT ANALYSIS, 2011-2015
Authors: Ahmed Mahmood, Hasnan M. Ijaz, Muhammad Uzair Lodhi, Vivek Nadipalli, Sohail Khan, Thomas Alexander
Journal: Journal of the American College of Cardiology (2022)
A large-scale systematic survey reveals recurring molecular features of public antibody responses to SARS-CoV-2
Authors: Yiquan Wang, Meng Yuan, Huibin Lv, Jian Peng, Ian A. Wilson, Nicholas C. Wu
Journal: Immunity (2022)

Global research to combat the COVID-19 pandemic has led to the isolation and characterization of thousands of human antibodies to the SARS-CoV-2 spike protein, providing an unprecedented opportunity to study the antibody response to a single antigen. Using the information derived from 88 research publications and 13 patents, we assembled a dataset of ∼8,000 human antibodies to the SARS-CoV-2 spike protein from >200 donors. By analyzing immunoglobulin V and D gene usages, complementarity-determining region H3 sequences, and somatic hypermutations, we demonstrated that the common (public) responses to different domains of the spike protein were quite different. We further used these sequences to train a deep-learning model to accurately distinguish between the human antibodies to SARS-CoV-2 spike protein and those to influenza hemagglutinin protein. Overall, this study provides an informative resource for antibody research and enhances our molecular understanding of public antibody responses.
Small Molecule Inhibitors of Nuclear Export and the Amelioration of Lupus by Modulation of Plasma Cell Generation and Survival
Authors: Javier Rangel‐Moreno, Maria de la Luz Garcia‐Hernandez, Teresa Owen, Jennifer Barnard, Enrique Becerril‐Villanueva, Trinayan Kashyap, Christian Argueta, Armando Gamboa‐Dominguez, Sharon Tamir, Yosef Landesman, Bruce I. Goldman, Christopher T. Ritchlin, Jennifer H. Anolik
Journal: Arthritis & Rheumatology (2022)

Objective To investigate the hypothesis that selective inhibitors of nuclear export (SINE compounds), recently approved for treatment of refractory plasma cell (PC) malignancy, may have potential in the treatment of lupus. Methods Female NZB/NZW mice were treated with the SINE compound KPT‐350 or vehicle control. Tissue specimens were harvested and analyzed by flow cytometry, using standard markers. Nephritis was monitored by determining the proteinuria score and by histologic analysis of kidney specimens. Serum anti–double‐stranded DNA (anti‐dsDNA) levels were measured by enzyme‐linked immunosorbent assay, and total numbers of IgG‐secreting and dsDNA‐specific antibody‐secreting cells were assessed by enzyme‐linked immunospot assay. Results KPT‐350 abrogated murine lupus nephritis at both early and late stages of the disease and rapidly impaired generation of autoreactive PCs in germinal centers (GCs). SINE compounds inhibited the production of NF‐κB–driven homeostatic chemokines by stromal cells, altering splenic B and T cell strategic positioning and significantly reducing follicular helper T cell, GC B cell, and autoreactive PC counts. KPT‐350 also decreased levels of cytokines and chemokines involved in PC survival and recruitment in the kidney of lupus‐prone mice. Exportin 1, the target of SINE compounds, was detected in GCs of human tonsils, splenic B cells of lupus patients, and multiple B cell subsets in the kidneys of patients with lupus nephritis. Conclusion Collectively, our results provide support for the therapeutic potential of SINE compounds, via their targeting of several molecular and cellular pathways critical in lupus pathogenesis, including autoantibody production by plasma cells.
A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer
Authors: C. E. Fletcher, L. Deng, F. Orafidiya, W. Yuan, M. P. G. S. Lorentzen, O. W. Cyran, A. Varela-Carver, T. A. Constantin, D. A. Leach, F. M. Dobbs, I. Figueiredo, B. Gurel, E. Parkes, D. Bogdan, R. R. Pereira, S. G. Zhao, A. Neeb, F. Issa, J. Hester, H. Kudo, Y. Liu, Y. Philippou, R. Bristow, K. Knudsen, R. J. Bryant, F. Y. Feng, S. H. Reed, I. G. Mills, J. de Bono, C. L. Bevan
Journal: Molecular Cancer (2022)

Abstract Background miR-346 was identified as an activator of Androgen Receptor (AR) signalling that associates with DNA damage response (DDR)-linked transcripts in prostate cancer (PC). We sought to delineate the impact of miR-346 on DNA damage, and its potential as a therapeutic agent. Methods RNA-IP, RNA-seq, RNA-ISH, DNA fibre assays, in vivo xenograft studies and bioinformatics approaches were used alongside a novel method for amplification-free, single nucleotide-resolution genome-wide mapping of DNA breaks (INDUCE-seq). Results miR-346 induces rapid and extensive DNA damage in PC cells - the first report of microRNA-induced DNA damage. Mechanistically, this is achieved through transcriptional hyperactivation, R-loop formation and replication stress, leading to checkpoint activation and cell cycle arrest. miR-346 also interacts with genome-protective lncRNA NORAD to disrupt its interaction with PUM2, leading to PUM2 stabilisation and its increased turnover of DNA damage response (DDR) transcripts. Confirming clinical relevance, NORAD expression and activity strongly correlate with poor PC clinical outcomes and increased DDR in biopsy RNA-seq studies. In contrast, miR-346 is associated with improved PC survival. INDUCE-seq reveals that miR-346-induced DSBs occur preferentially at binding sites of the most highly-transcriptionally active transcription factors in PC cells, including c-Myc, FOXA1, HOXB13, NKX3.1, and importantly, AR, resulting in target transcript downregulation. Further, RNA-seq reveals widespread miR-346 and shNORAD dysregulation of DNA damage, replication and cell cycle processes. NORAD drives target-directed miR decay (TDMD) of miR-346 as a novel genome protection mechanism: NORAD silencing increases mature miR-346 levels by several thousand-fold, and WT but not TDMD-mutant NORAD rescues miR-346-induced DNA damage. Importantly, miR-346 sensitises PC cells to DNA-damaging drugs including PARP inhibitor and chemotherapy, and induces tumour regression as a monotherapy in vivo, indicating that targeting miR-346:NORAD balance is a valid therapeutic strategy. Conclusions A balancing act between miR-346 and NORAD regulates DNA damage and repair in PC. miR-346 may be particularly effective as a therapeutic in the context of decreased NORAD observed in advanced PC, and in transcriptionally-hyperactive cancer cells.
MICRO RNA 155:126 RATIO AS A MARKER OF CLINICALLY MANIFEST ATHEROSCLEROSIS ACROSS DIFFERENT AGE GROUPS AND RISK FACTOR PROFILES
Authors: Arnab Banerjee, Debabrata Roy, Hindol Mazumdar, Rudranil Bhowmik, Sanmoy Karmakar, Kaushik Manna, Abhishek Roy, Navanil Biswas, Subhashis Dey, Disharee Das
Journal: Journal of the American College of Cardiology (2022)